Skip to main content
. Author manuscript; available in PMC: 2021 Apr 27.
Published in final edited form as: Cancer Biomark. 2020;27(3):407–421. doi: 10.3233/CBM-190988

Fig. 1.

Fig. 1.

Western blot of healthy control serum and early stage HGSOC serum diluted at 1:300 with 7 antigens in Validation I study. A. Secondary antibody anti-HIS tag IgG loading control. B. Secondary antibody anti-human IgG. Scans quantified on Odyssey software; background-corrected integrated intensity of anti-human IgG antibody (IRDye800) normalized as ratio to anti-His tag antibody (IRDye700) per antigen.